Double Bond Pharmaceutical International Ab Class BNGM: DBP.B

DBP.B: Revenue and net loss improved, with strong project progress and a major rights issue launched

· Issued by Double Bond Pharmaceutical International Ab Class B

Revenue and net results improved significantly year-over-year, driven by progress in key projects and new partnership opportunities. A major rights issue was launched, and the company is accelerating development of its pipeline, especially S1053 and SA033.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

Earlier from Double Bond Pharmaceutical International Ab Class B

All Double Bond Pharmaceutical International Ab Class B news releases